摘要
Abstract
Objective:To explore the clinical efficacy of Guanxin Shutong Capsules and Atorvastatin in patients with acute myocardial infarction(AMI)and H-type hypertension(HHT).Method:A total of 88 patients with AMI and HHT from April 2021 to January 2024 who were admitted in Mudanjiang Medical University Affiliated Second Hospital were selected and randomly divided into the study group(44 cases)and the control group(44 cases).The control group was treated with Atorvastatin,the study group was treated with Guanxin Shutong Capsules and Atorvastatin.The myocardial infarction thrombolysis test(TIMI)blood flow grading,myocardial enzyme spectrum indicators,serum indicators,adverse reactions,and major adverse cardiovascular events(MACE)were compared between the two groups.Result:After treatment,in the TIMI blood flow grading,in comparison of the control group,that in the study group was better,the difference was statistically significant(P<0.05).After treatment,the lactate dehydrogenase(LDH)and cardiac troponin I(cTnI)in both groups were decreased,and in comparison of the control group,those in the study group were lower,the differences were statistically significant(P<0.05).After treatment,the interleukin-8(IL-8),vascular cell adhesion molecule-1(VCAM-1),growth differentiation factor-15(GDF-15)levels in both groups were decreased,and in comparison of the control group,those in the study group were lower,the differences were statistically significant(P<0.05).In the incidence of adverse reactions,there was no statistically significant difference in both groups(P>0.05).In the incidence of MACE,in comparison of the control group(27.27%),that in the study group(9.09%)was lower,the difference was statistically significant(P<0.05).Conclusion:Treatment with Guanxin Shutong Capsules and Atorvastatin in AMI patients with HHT can effectively improve blood perfusion status,myocardial enzyme spectrum indicators,serum indicators,reduce MACE,and has high safety.关键词
冠心舒通胶囊/阿托伐他汀/急性心肌梗死/H型高血压Key words
Guanxin Shutong Capsules/Atorvastatin/Acute myocardial infarction/H-type hypertension
